REG - Premaitha Health PLC - Holding(s) in Company <Origin Href="QuoteRef">NIPT.L</Origin>
14/02/2018 10:30
For best results when printing this announcement, please click on the link
below:
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20180214:nRSN8716Ea
RNS Number : 8716E
Premaitha Health PLC
14 February 2018
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Premaitha Health plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments X
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name Life Technologies Limited, a company incorporated in Scotland with company number SC083107
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi: 9 February 2018
6. Date on which issuer notified (DD/MM/YYYY): 13 February 2018
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments Total of both in % (8.A + 8.B) Total number of voting rights of issuervii
(total of 8.B 1 + 8.B 2)
Resulting situation on the date on which threshold was crossed or reached 29.79% (based on current share capital) and 22.95% (based on so-enlarged share capital) 321,218,279 (based on current share capital) and 416,906,985 (based on so-enlarged share capital)
Position of previous notification (if applicable) 25.92% (based on current share capital) and 19.97% (based on so-enlarged share capital)
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of Number of voting rightsix % of voting rights
sharesISIN code (if possible)
Direct(Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1) Direct(Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
SUBTOTAL 8. A
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration Exercise/ Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights
datex Conversion Periodxi
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration Exercise/ Physical or cash settlementxii Number of voting rights % of voting rights
datex Conversion Period xi
Warrants 11 December 2023 Exercisable up to 11 December 2023 Physical 20,325,204 6.33% (based on current share capital) and 4.88% (based on so-enlarged share capital)
Warrants 11 December 2023 Exercisable up to 11 December 2023 Physical 17,094,018 5.32% (based on current share capital) and 4.10% (based on so-enlarged share capital)
Warrants 11 December 2023 Exercisable up to 11 December 2023 Physical 16,913,319 5.27% (based on current share capital) and 4.06% (based on so-enlarged share capital)
Warrants 11 December 2023 Exercisable up to 11 December 2023 Physical 28,938,797 9.01% (based on current share capital) and 6.94% (based on so-enlarged share capital)
Warrants 11 December 2023 Exercisable up to 11 December 2023 Physical 12,417,368 3.87% (based on current share capital) and 2.98% (based on so-enlarged share capital)
SUBTOTAL 8.B.2 95,688,706 29.79% (based on current share capital) and 22.95% (based on so-enlarged share capital)
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the X
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Thermo Fisher Scientific Inc. 29.79% (based on current share capital) and 22.95% (based on so-enlarged share capital)
Thermo Fisher Scientific Life Holdings Limited 29.79% (based on current share capital) and 22.95% (based on so-enlarged share capital)
Life Technologies Limited 29.79% (based on current share capital) and 22.95% (based on so-enlarged share capital)
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi
Place of completion London, United Kingdom
Date of completion 13 February 2018
This information is provided by RNS
The company news service from the London Stock ExchangeRecent news on Yourgene Health
See all newsREG - Velay Financial - Form 8.3 - YOURGENE HEALTH PLC
AnnouncementREG - AIM Yourgene Health PLC - Cancellation - Yourgene Health plc
AnnouncementREG - Yourgene Health PLC - De-listing and cancellation of trading of Shares
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
Announcement